Develop bioprosthetic tissue-based solutions for venous disease. Focus on enhancing the standard of care in the treatment of venous disease. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly above the class average — a step short of the very top.
There is growth, but not at top-of-the-class tempo.
Clearly below the class average.
Business Quality: Profit power and business quality trail similar companies in the sector.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
An investor who bought at the very peak is down 97% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Our checks did not surface a specific strength to highlight here.
A loss of $19.5M against $0 in annual sales.
At the current pace of spending, the cash lasts about 1.4 years. After that, the company needs to find new money.
On our five-subject report card, NVNO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: NVNO is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: the revenue breakdown.